FindTrial
Sign In

Assessment of the safety of long-term nicotinamide mononucleotide (NMN) in healthy subjects; phase II study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims.

Assessment of the safety of long-term nicotinamide mononucleotide (NMN) in healthy subjects; phase II study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims. - Assessment of the safety of long-term nicotinamide mononucleotide (NMN).

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030609
Enrollment
30
Registered
2017-12-29
Start date
2019-08-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

long-term (8 weeks) intake of NMN

Sponsors

Keio University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: the healthy subjects who agree to the study.

Exclusion criteria

Exclusion criteria: 1 the subjects with a previous history of diseases. 2 the subjects with malignant neoplasms. 3 the subjects with serious infections. 4 the subjects with psychiatric disorders. 5 the subjects with ophthalmic disorder. 6 the subjects with allergic disorders. 7 the subjects who are regarded as inadequate by the investigator. 8 the subjects who have obvious abnormality in the screening test

Design outcomes

Primary

MeasureTime frame
the safety of long-term (8weeks) NMN (physical and laboratory examinations).—

Secondary

MeasureTime frame
1.the kinetics of NMN and metabolites of nicotinamide. 2.the effect of daily NMN admnistration on glucose metabolism—

Countries

Japan

Contacts

Public ContactMasanori Mitsuishi

Keio University School of Medicine Division of Endocrinology, Metabolism and Nephrology

mitsumasa@keio.jp03-5363-3797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026